Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For any potential investors who have yet to begin DD please listen to the presentation. Their technology is living up to expectations in market. Production and logistic chelae goes are well understood and manageable.
This is an excellent opportunity, transitioning from development into operational phase, ready to profit. IEVM will do well in the Oil and Gas industry and with a strong revenue stream will expand to food service and medical industries.
Thanks for posting the link.
What news are they selling on? What, in your opinion, has been publicly released that motivates the sell off?
A week's worth of good will lost in a day. Not the best way to go into the weekend but holding tight.
Rough day. Time will tell. Looking forward to USAMRIID feedback.
GLTA longs.
Another strong day. Good volume, nice closing price. IEVM showing strong signs (if not strong sp growth), since December.
Thanks for the info. Good to see institutional growth continue to grow.
GLTA longs.
I like the combination of high volume and sp gain. Looking good.
The Midtown Partners report posted to Nanoviricides' website is an excellent source for potential investors.
GLTA longs.
The weekend is over USAMRIID. Back to work.
Go NNVC. GLTA longs.
Another day closer to EbolaCide 2 results.
GLTA longs.
Are you referring to Friday's 8k?
Hard to know when the boot will drop. USAMRIID will work at their pace, per their priorities. Pressure from Sen. Blumenthal may influence timing but that's purely speculation.
Regardless of timing we've arrived at a major crossroad. Ebola, as has been reported in the news and reinforced by both supporters and detractors on this board, is a formidable foe. If NNVC is successful with EbolaCide2 those who appreciate the mechanism of action for all viricides will know that the vote of confidence validates the claims made for FluCide, DengueCide and the balance of formulas designed by Dr. Diwan and team.
These are exciting times for NNVC longs. Those of us who have accumulated over the years, who rest comfortably in profit having held tight and averaged down, don't have long to wait.
A positive USAMRIID outcome combined with BASi's favorable preliminary toxicity results will validate years of preclinical NNVC-internal and various external research. Negative results and well, our speculative enterprise may come to an end. The share price will surely take a hit and a strategic regroup will be needed.
GLTA, be patient, hold tight and keep your fingers crossed.
I see the company's financing as a sign that demand is driving requirements to ramp up operations. Thumbs up.
Held on well to yesterday's gains. GLTA longs.
Expecting? More like anticipating a small revenue number.
Reading comprehension is not an issue.
USAMRIID tested EbolaCide1, agreed to test EbolaCide2.
Awaiting results.
GLTA.
USAMRIID reported EbolaCide as effective. I'll take their word and their decision to invest time and resources in testing EbolaCide2 as a positive indicator.
Each investor should conduct their own DD and make their own investment decisions.
http://www.upi.com/Business_News/Security-Industry/2008/02/19/USAMRIID-finds-Ebola-drug-effective/11611203449127/
I am looking forward to USAMRIID's test results. I think it speaks volumes that USAMRIID has engaged in a second round of testing. Their finding is 2009-10, that EbolaCide1, was very effective says it all. USAMRIID would not be testing EbolaCide2 if they did not have confidence that the improvements in formulation inspired by recent Ebola research have real potential.
I will be very pleased with the positive results even if the market yawns.
Perhaps folks are waiting on earnings reported and care little for earnings projected.
I had concerns related to oil industry slow down. I held hope that optimizing well efficiency would preserve IEVM's opportunity. The recent PR addresses this issue to my satisfaction. I would go so far as to say that as drillers slow their pace they will turn their attention to improving methods and procedures at existing wells. The growth in number of supported wells reported by IEVM implies drillers are getting a return on their investment. If keeping their wells clean, reducing maintenance and extending maintenance and repair cycles is the result of using IEVM's product then there's potential to grow the business.
Maybe the annual report, if revenue has been recognized in Q4, will get a market reaction.
Hard to figure. I thought the PR yesterday would be received positively. Go figure.
Sorry, that's New Mexico not Texas.
Excellent news. 200% well increase in Utah, 400% well increase in Texas. Revenue estimates +$500,000 this year.
I would speculate that the shape of the virus is not as important as the shape and flexibility of the host cell, and more importantly for investors, the mimic micelle that the virus will attach to.
Is the host cell, the human cell to which Ebola attaches, shaped to complement Ebola? Is the NanoViricide micelle shape in such a way to mimic the host cell? Designing a mimic that replicates the vulnerable host cell is the challenge.
Are the attachment proteins on the host cell optimized to encourage Ebola attachment? Is the viricide Ebola-specific coating designed to mimic the host cell attachment characteristics?
It is Ebola that accommodates the existing characteristics of the host cell. Nanoviricides' micelle and it's chemical coating is designed to mimic the characteristics of the host cell. Will the Ebola virus bind to the mimic? If Dr. Diwan has designed Ebolacide correctly Ebola will attach regardless of its unique shape and cell characteristics. The peculiar shape of the Ebola virus does not prevent it from flexing and bending to attach to a host cell. Therefore Ebola has the capacity to bend and flex to accommodate the shape and characteristics of EbolaCide.
NNVC has been called a lifestyle company, management has been disparaged, every misstep and delay has been catalogued and cited to beat the stock price down. Supporters have countered and cajoled to keep the price up. (To the extant that iHub chatter can effect the price.)
In recent months NanoViricide has put their science on the line. BASi has preformed preliminary FluCide Tox testing.
USAMRIID is conducting EbolaCide efficacy testing.
Before Q2 is over Bears and Bulls will have these provisional 3rd party results to determine their investment position.
Tell that to the families of 2015’s victims.
KarinCA, your research into Dr Menon is deeply appreciated. His credentials are considerable and have often been cited on iHub message boards. Despite this, some have disparaged him, for their own benefit, on iHub. A restatement of his bone fides by an iHub community member a well respected as you should put the slanders to rest.
Thank you Karin, your contributions to this board (and others), are deeply valued.
Thank you for the detailed review.
Ebola was added to the FDA Orphan list in December. Passed congress and signed by the PoTUS without a fuss. Opportunity.
Public space, private space? When the mud gets tracked into shared space it's understandable for those who honor civil, respectful discourse to feel sullied. The discourse becomes too often diss and course.
Happy New Years to all NNVC supporters. GLTA.
Now that's funny.
The say duh... as if the president's statement reflects a late arriving awareness of what you believe is common knowledge fails to appreciate the role of the bully pulpit. Presidents, past and current, Democratic and Republican, use the power of the office to elevate issues such as the Ebola outbreak not as a means of revelation but as a means to signal the need for, and often forthcoming, multi-national governmental action.
The president's statement is a signal that the USA acknowledges the humanitarian crisis and the regional, if not global, risk presented. It is a call to action.
As a nation we have often been late to officially recognize and engage in efforts to contain and eradicate global health crisis. One could argue that the call to action should have come sooner. I am please that the pronouncement has been made. In this instance I hope politics will be put aside so the capabilities and resources of this great nation might be directed to ending the Ebola crisis.
"Duh" doesn't contribute to a solution.
I am limited to a single NNVC post per day. Yesterday I spent that allotment clarifying a point of debate when I felt those engaged where talking past one another. I did not comment on the merit of the original concern raised by ZF. I am unqualified to comment on the legitimacy of his concern. Others on the board are far more qualified and I benefit by their posts regularly.
Regardless of which side was taken in the debate, Pro= no concern, any unintended competition with normal cellular function will be insignificant as indicated in 6000 animal tests. OR Con= the question is the smoking gun and proof of what everyone know already...Tox will fail and the house of cards will collapse, the question must ultimately be answered in BASi formal Toxicity testing.
Whatever your bias may be, I am 5 years long and a committed supporter, independent testing must be conducted to provide some assurance that patients will be safe. Independent testing must be conducted to separate or validate what we want to be true from the unbiased truth.
I am grateful for the education I have received participating on this board for the past few years. I am often annoyed by the lack of civility but nothing comes for free and the annoyance is my tuition. Some may bemoan the fact that yesterday's debate has been had before. I for one was very pleased by a day of substanitive discussion highlighted by one or two posts that explained likely implications of unintended viricide to non-virus linkage. Thank you for another lesson.
Looking forward to Tox testing and if all goes well phase I/II. GLTA longs.
I believe ZF is expressing the following concern;
the lock on the host cell is designed for a purpose. Perhaps when the host is healthy the lock is essential for a required nutrient to attach and enter the host cell. A virus introduced into the host has a key that exploits the lock, enters the host cell and replicates. The virus has a key similar to the key on the nutrient cell.
Now introduce a viricide. The virus links to the viricide lock. The virus spends itself on the decoy viricide. Additionally, trillions of viricides circulating in the blood stream also link to the nutrient originally targeted for the host cell. Is the host cell deprived of an essential nutrient? Will the host suffer for this deprivation? Given the number of viricides and the time they remain active in the host blood does this viricide/nutrient interaction introduce risk to the host?
I agree the stock, lightly traded, is subject to extreme fluctuation and may see.06 before seeing .12. Revenue reporting, or signed contracts that guarantee same, is the news that shareholder need.
Exelixis announce P3 for prostate cancer failed to achieve anticipated results.
Nice gains in August. Steady SP growth since June. This stock has been here before. I hope the growth spurring this particular pattern is being driven by those who see real business expansion in the Oil patch.
GLTA.